Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2b TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY IN HEALTHY INFANTS 2 AND 6 MONTHS OF AGE

NCT04645966 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04645966
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04645966 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2b TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY IN HEALTHY INFANTS 2 AND 6 MONTHS OF AGE
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
November 26, 2020
Completion date
September 15, 2022
Enrollment
326 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal vaccine